1-9 of 9
Monica Hellesøy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting Venetoclax Resistance in TP53 -Mutated Acute Myeloid Leukemia

Ida Vänttinen, Tanja Ruokoranta, Joseph J Saad, Sari Kytölä, Monica Hellesøy, Stein-Erik Gullaksen, Pia-Sofia Ettala, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Krister Wennerberg, Bjorn T. Gjertsen, Caroline A. Heckman, Mika Kontro, Heikki Kuusanmäki
Journal: Blood
Blood (2023) 142 (Supplement 1): 2927.
https://doi.org/10.1182/blood-2023-189340
Published: 2023
Journal Articles

Bemcentinib (Oral AXL Inhibitor) in Combination with Low-Dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients.Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results Indicating Bemcentinib Elicits Anti-AML Immune Responses

Sonja Loges, Grerk Sutamtewagul, Michael Heuser, Jörg Chromik, Silke Kapp-Schwoerer, Monica Crugnola, Nicola Di Renzo, Roberto M. Lemoli, Daniele Giovanni Mattei, Isabel Ben Batalla, Monica Hellesøy, Jonas Waizenegger, Melanie Janning, Charles D. Imbusch, Niklas Beumer, Austin Rayford, Jaya Nautiyal, Tzivia Berkman-Gottlieb, David Micklem, Hani Gabra, Claudia Gorcea-Carson, James B. Lorens, Walter Fiedler, Yesid Alvarado, Bjorn T. Gjertsen, Lisa-Marie Rieckmann
Journal: Blood
Blood (2021) 138 (Supplement 1): 3410.
https://doi.org/10.1182/blood-2021-147225
Published: 2021
Journal Articles

The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)

Sonja Loges, MD PhD, Michael Heuser, Jörg Chromik, MD, Carlos Enrique Vigil, MD, Peter Paschka, MD, Francesca Re, MD, Nicola Di Renzo, MD, Roberto M. Lemoli, Daniele Giovanni Mattei, MD, Isabel Ben-Batalla, PhD, Monica Hellesoy, PhD, Katherine Lorens, MD, Joseph Birkett, PhD, Stuart McPherson, BSc, Jaya Nautiyal, PhD, David Micklem, PhD, Hani Gabra, MD PhD FRCPE, FRCP, James B. Lorens, PhD, Walter Fiedler, MD, Yesid Alvarado, MD, Bjorn T. Gjertsen, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 14.
https://doi.org/10.1182/blood-2020-136566
Published: 2020
Journal Articles

Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study

Sonja Loges, MD, PhD, Michael Heuser, MD, Jörg Chromik, MD, Carlos Enrique Vigil, MD, Peter Paschka, MD, Francesca Re, Nicola Di Renzo, MD, Roberto Massimo Lemoli, MD, Daniele Giovanni Mattei, MD, Isabel Ben Batalla, PhD, Monica Hellesoy, PhD, David Micklem, PhD, Robert J. Holt, PhD, James B. Lorens, PhD, Muhammad Shoaib, MD, Hassan Aly, MD PhD, Wouter Hanekom, MD, Walter Fiedler, MD, Jorge E. Cortes, MD, Bjorn T. Gjertsen, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3943.
https://doi.org/10.1182/blood-2019-128683
Published: 2019
Journal Articles

A 36-Dimensional Cytometry by Time of Flight (CyTOF) Analysis of De Novo Acute Myeloid Leukemia (AML) Patients Eligible for Intensive Chemotherapy

Benedicte Sjo Tislevoll, MD, Oda Helen Eck Fagerholt, Nello Blaser, MS, PhD, Monica Hellesøy, MS, PhD, Stein-Erik Gullaksen, MS, PhD, Pilar Ayuda Duran, MS, PhD, Laure Isabelle Piechaczyk, MS, Dagim Tadele, MS, Jørn Skavland, MS, PhD, Sonia Gavasso, MS, PhD, Jorrit Enserink, MS, PhD, Yngvar Fløisand, MD PhD, Bjorn Gjertsen, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1502.
https://doi.org/10.1182/blood-2018-99-116943
Published: 2018
Journal Articles

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Muntasir M Majumder, MSc, BPharm, Maija Leppä, MSc(Tech), Monica Hellesoy, PhD, Paul Dowling, BSc, PhD, Alina Malyutina, Despina Bazou, BSc, MSc, PhD, Emma Irene Andersson, MSc, Alun Parsons, Jing Tang, PhD, Olli Kallioniemi, MD PhD, Satu Mustjoki, MDPhD, Peter O'Gorman, MD PhD FRCP, FRCPath, Krister Wennerberg, PhD, Kimmo Porkka, MD PhD, Bjorn Gjertsen, MD PhD, Caroline A Heckman, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 264.
https://doi.org/10.1182/blood-2018-99-118242
Published: 2018
Journal Articles

Development of Novel Highly Specific FLT3 Targeted Inhibitors for Combination or Sequential Therapy of Acute Myeloid Leukemia

Misbah Sabir, MSc, Monica Hellesoy, PhD, Jarno Kivioja, MSc, Caroline Engen, MD, Claire Amiable, Mihaela Popa, Remi Guillon, Øystein Bruserud, MD PhD, Caroline A Heckman, PhD, Emmet McCormack, BSc, PhD, Dominique Surleraux, Bjørn Tore Gjertsen
Journal: Blood
Blood (2017) 130 (Supplement 1): 3349.
https://doi.org/10.1182/blood.V130.Suppl_1.3349.3349
Published: 2017
Journal Articles

Single Cell Signaling Pharmacodynamics in a Phase 1b Trial of the Axl Inhibitor BGB324 in Acute Myeloid Leukemia

Monica Hellesøy, PhD, Stein-Erik Gullaksen, Benedicte Sjo Tislevoll, Oda Helen Eck Fagerholt, Hakon Reikvam, MD PhD, Sonja Loges, MD PhD, Jorge Cortes, MD, Michael Heuser, MD, Jörg Chromik, Jørn Skavland, PhD, André Sulen, Øystein Bruserud, MD PhD, Jim Lorens, PhD, Gro Gausdal, PhD, David Micklem, Bjorn T. Gjertsen, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3995.
https://doi.org/10.1182/blood.V128.22.3995.3995
Published: 2016
Journal Articles

Single Cell-Level Signaling Profiling of Acute Myeloid Leukemia Following Treatment with Axl Kinase Inhibitor BGB324

Monica Hellesøy, PhD, Katarzyna Wnuk-Lipinska, PhD, Anna Boniecka, MSc, Eline Milde Nævdal, Hakon Reikvam, MDPhD, Sonja Loges, MDPhD, Jorge E. Cortes, MD, Jørn Skavland, PhD, Øystein Bruserud, MDPhD, Jim Lorens, PhD, David Micklem, PhD, Gro Gausdal, PhD, Bjorn T. Gjertsen, MD PhD
Journal: Blood
Blood (2015) 126 (23): 4931.
https://doi.org/10.1182/blood.V126.23.4931.4931
Published: 2015